current position> Organization > Research Centesr > Glycomedicine Technology Research Center > Strategic Themesmenu skip


Glycomedicine Technology Research Center

Research Themes -Strategic Themes

1. Targeting technology using biological materials

Targeting technology using biological materials As therapeutics, biological materials including carbohydrates, lipids, proteins and nucleic acids are generally less toxic to humans than synthetic materials and are environmentally friendly. In this research center, we aim at identifying disease specific and targeted therapeutics using biologically sustainable materials such as short peptides by screening peptide-displaying phage libraries (figure shown on left).
 Peptide-display phage technology provides an extremely useful resource for drug discovery.  However, library screening can be challenging, limiting its use in translational research.  We will standardize procedures used for peptide-display library screening and employ automation, with the goal of making the technique more useful as a drug discovery tool to a wide range of researchers. 

2. Development of evaluation means for targeting technology

 Development of evaluation strategy of targeting technology In the development of the glycoprotein-targeted diagnostics and therapeutics, the quantitative analysis of the binding affinity between the glycoprotein and its probe should be conducted. It is also necessary to evaluate the pharmacokinetics and the accumulation of the probe to the targeted organs. The affinity between the glycan and the probe is relatively weak compared with the affinity of antibodies; therefore, a novel quantitative analysis technology is required.  We designated strategic theme 2 as the improvement of the probes through the development of technology for determination of the binding affinity of the probe in solution and evaluation of pharmacokinetics in cells, tissues, and model animal.

3. Development of technology for discovering disease glycoforms

 Lesional cells are known to express certain glycan structures ectopically , e.g., enhanced branching, polylactosamine, fucosylation, sialylation, and sulfation, in association with infection, carcinogenesis, or environmental stresses. Therefore, a tissue-specific glycoprotein carrying the glycan structures which emerged ectopically in the lesion, called as “disease glycoform”, must be a good biomarker of the disease. In this strategic study, we develop and miniaturize the methods to capture, identify, verify their structures, and quantify disease glycoforms for disease glycobiomarker development.

Inquiry (Administrative)

Glycomedicine Technology Research Center (GTRC)
National Institute of Advanced Industrial Science and Technology (AIST)

Central 2, 1-1-1, Umezono, Tsukuba, Ibaraki, 305-8568, Japan
TEL: +81-29-861-3253 FAX: +81-29-861-3252